An Open-label, Randomized, Three-period Crossover, Single Dose Study to Compare the Pharmacokinetics of the Final EC905 Formulation to Marketed Solifenacin (Vesicare and Tamsulosin OCAS (Omnic OCAS)
Latest Information Update: 17 Sep 2021
At a glance
- Drugs Solifenacin/tamsulosin (Primary) ; Solifenacin; Tamsulosin
- Indications Benign prostatic hyperplasia
- Focus Pharmacokinetics
- Sponsors Astellas Pharma
- 09 Oct 2013 New trial record